CD4+ T cells and immune ageing; major players and predictors for disease activity in giant cell arteritis

CD4+ T cells and immune ageing; major players and predictors for disease activity in giant cell arteritis - CD4+ T cells and immune ageing in giant cell arteritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44732

Enrollment

1500

Registered

2010-09-13

Start date

2010-10-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large vessel vasculitis and Polymyalgia rheumatica

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: GCA patients 1. Fulfilling ACR criteria for GCA 2. Not yet treated with corticosteroids 3. Age >= 50 years 4. Being able to give informed consent GCA patients in remission 1. Fulfilling ACR criteria for GCA 2. Age >= 50 years 3. Being able to give informed consent ;PMR patients 1. Fulfilling Healey criteria for PMR 2. Not yet treated with corticosteroids 3. Age >= 50 years 4. Being able to give informed consent ;PMR patients in remission 1. Fulfilling Healey criteria for PMR 2. Age >= 50 years 3. Being able to give informed consent ;Healthy controls 1. Having no chronic disease 2. Age >= 50 years 3. Being healthy according to SENIEUR protocol 4. Being able to give informed consent;Infectious controls 1. Having no chronic disease 2. Age >= 50 years 3. Being healthy according to SENIEUR protocol, exept for an urinary tract or upper airway infection 4. Being able to give informed consent

Exclusion criteria

Exclusion criteria: GCA patients 1. Not fulfilling the ACR criteria for GCA 2. Concomitant chronic diseases that may affect immune system (such as prior or current malignant disease, active infectious disease, other rheumatological disease, kidney disease, active allergy etc.) ;PMR patients 1. Not fulfilling Healey criteria for PMR 2. Concomitant chronic diseases that may affect immune system (such as prior or current malignant disease, active infectious disease, other rheumatological disease, kidney disease, active allergy etc.) ;Healthy controls 1. Having chronic diseases 2. Not being healthy according to SENIEUR protocol;Infectious controls 1. Having chronic diseases 2. Not being healthy according to SENIEUR protocol, except for an urinary or upper airway infection.;GCA patients, PMR patients, healthy and infectious controls 1. No informed consent 2. Severe anaemia defined as a Hb of less than 6,0 g/dL

Design outcomes

Primary

Measure	Time frame
Is there a relation between CD4+ T cell subset diversity and GCA?	—

Secondary

Measure	Time frame
- Which cell subsets migrate into the arterial wall in GCA? - Are there any biomarkers (CD4+ T cell subsets, cytokines, IRP) predicting relaps in GCA patients? - Is there a relation between the IRP and frailty? - Are there any biomarkers (CD4+ T cell subsets, cytokines, IRP) that distinguish PMR patients from GCA patients, or from patients that have both diseases? - Which cell subsets migrate into the joints of PMR patients? - Are there shifts in the cell subsets in GCA and PMR patients in remission - Which genes are involved in the pathogenesis of GCA and PMR	—

Measure

Time frame

- Which cell subsets migrate into the arterial wall in GCA? - Are there any biomarkers (CD4+ T cell subsets, cytokines, IRP) predicting relaps in GCA patients? - Is there a relation between the IRP and frailty? - Are there any biomarkers (CD4+ T cell subsets, cytokines, IRP) that distinguish PMR patients from GCA patients, or from patients that have both diseases? - Which cell subsets migrate into the joints of PMR patients? - Are there shifts in the cell subsets in GCA and PMR patients in remission - Which genes are involved in the pathogenesis of GCA and PMR

—

Countries

Netherlands

Outcome results